Market Overview

Why Heron Therapeutics's Stock Is Trading Higher Today


Heron Therapeutics (NASDAQ: HRTX) shares are trading higher on Wednesday after Guggenheim initiated coverage on the company's stock with a Buy rating and $24 price target.

Heron Therapeutics is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL and CINVANTI. Its pipeline product is HTX-011.

Heron Therapeutics’s shares were up 0.49% at $18.53 at the time of publication. The stock has a 52-week high of $26.81 and a 52-week low of $9.60.

Related Links:

UK Clears Gilead's Remdesivir For Some Coronavirus Patients

Moderna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate Annually


Related Articles (HRTX)

View Comments and Join the Discussion!

Posted-In: why it's movingBiotech News General